Merck & Co., Inc. Website

Merck & Co., Inc.

NYSE-MRK

Basic

  • Market Cap

    $327.97B

  • EV

    $356.63B

  • Shares Out

    2,532.81M

  • Revenue

    $61.4B

  • Employees

    71,000

Margins

  • Gross

    74.85%

  • EBITDA

    34.54%

  • Operating

    28.55%

  • Pre-Tax

    6.37%

  • Net

    3.76%

  • FCF

    17.98%

Returns (5Yr Avg)

  • ROA

    9.82%

  • ROTA

    57.07%

  • ROE

    28.12%

  • ROCE

    21.39%

  • ROIC

    16.33%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $141.88

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $5,619M

  • Net Debt

    $28.6B

  • Debt/Equity

    0.85

  • EBIT/Interest

    14.52

Growth (CAGR)

  • Rev 3Yr

    13.63%

  • Rev 5Yr

    7.35%

  • Rev 10Yr

    3.48%

  • Dil EPS 3Yr

    -31.33%

  • Dil EPS 5Yr

    -22.3%

  • Dil EPS 10Yr

    -5.11%

  • Rev Fwd 2Yr

    6.83%

  • EBITDA Fwd 2Yr

    81.06%

  • EPS Fwd 2Yr

    155.81%

  • EPS LT Growth Est

    38.25%

Dividends

  • Yield

  • Payout

    325.49%

  • DPS

    $2.96

  • DPS Growth 3Yr

    6.08%

  • DPS Growth 5Yr

    8.26%

  • DPS Growth 10Yr

    5.52%

  • DPS Growth Fwd 2Yr

    5.14%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Total Revenues

39,121

41,518

48,704

59,283

60,115

61,403

Total Revenues % Chg.

-7.5%

6.1%

17.3%

21.7%

1.4%

6.1%

Cost of Goods Sold, Total

11,060

11,990

13,466

17,206

15,915

15,442

Gross Profit

28,061

29,528

35,238

42,077

44,200

45,961

Selling General & Admin Expenses, Total

8,829

8,569

9,403

9,669

9,884

9,839

R&D Expenses

8,594

10,564

11,942

11,918

18,342

18,592

Other Operating Expenses, Total

17,423

19,133

21,345

21,587

28,226

28,431

Operating Income

10,638

10,395

13,893

20,490

15,974

17,530

Interest Expense, Total

-893

-831

-806

-962

-1,146

-1,207

Interest And Investment Income

274

118

36

157

365

326

Net Interest Expenses

-619

-713

-770

-805

-781

-881

Income (Loss) On Equity Invest.

Currency Exchange Gains (Loss)

-187

-145

-297

-237

-370

-392

Other Non Operating Income (Expenses)

124

71

256

681

420

353.5

EBT, Excl. Unusual Items

9,956

9,608

13,082

20,129

15,243

16,610.5

Restructuring Charges

-915

-705

-868

-666

-933

-1,082

Merger & Related Restructuring Charges

-1,745

-4,288

-11,409

-10,873

Impairment of Goodwill

-162

Gain (Loss) On Sale Of Investments

170

1,338

1,940

-1,419

340

33

Gain (Loss) On Sale Of Assets

Asset Writedown

-172

-90

-275

-1,600

-779

-779

In Process R&D Expenses

Legal Settlements

-573

-0.5

Other Unusual Items

39

EBT, Incl. Unusual Items

7,171

5,863

13,879

16,444

1,889

3,909

Income Tax Expense

1,565

1,340

1,521

1,918

1,512

1,590

Earnings From Continuing Operations

5,606

4,523

12,358

14,526

377

2,319

Earnings Of Discontinued Operations

4,153

2,548

704

Minority Interest

84

-4

-13

-7

-12

-13

Net Income

9,843

7,067

13,049

14,519

365

2,306

Net Income to Common Incl Extra Items

9,843

7,067

13,049

14,519

365

2,306

Net Income to Common Excl. Extra Items

5,690

4,519

12,345

14,519

365

2,306

Total Shares Outstanding

2,539

2,530.2

2,527.6

2,537.8

2,531.6

2,532.7

Weighted Avg. Shares Outstanding

2,565

2,530

2,530

2,532

2,537

2,535.8

Weighted Avg. Shares Outstanding Dil

2,580

2,541

2,538

2,542

2,547

2,545.3

EPS

3.8

2.8

5.2

5.7

0.1

0.9

EPS Diluted

3.8

2.8

5.1

5.7

0.1

0.9

EBITDA

13,715

13,613

17,016

24,279

19,706

21,211

Effective Tax Rate

21.8%

22.9%

11%

11.7%

80%

40.7%